Literature DB >> 27653566

Primary Sclerosing Cholangitis.

Konstantinos N Lazaridis1, Nicholas F LaRusso1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27653566      PMCID： PMC5553912          DOI： 10.1056/NEJMra1506330

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  73 in total

1.  Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.

Authors:  Alexander G Miethke; Wujuan Zhang; Julia Simmons; Amy E Taylor; Tiffany Shi; Shiva Kumar Shanmukhappa; Rebekah Karns; Shana White; Anil G Jegga; Celine S Lages; Stephenson Nkinin; Bradley T Keller; Kenneth D R Setchell
Journal:  Hepatology       Date:  2015-08-21       Impact factor: 17.425

2.  ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; M Edwyn Harrison
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

3.  Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.

Authors:  Espen Melum; Andre Franke; Christoph Schramm; Tobias J Weismüller; Daniel Nils Gotthardt; Felix A Offner; Brian D Juran; Jon K Laerdahl; Verena Labi; Einar Björnsson; Rinse K Weersma; Liesbet Henckaerts; Andreas Teufel; Christian Rust; Eva Ellinghaus; Tobias Balschun; Kirsten Muri Boberg; David Ellinghaus; Annika Bergquist; Peter Sauer; Euijung Ryu; Johannes Roksund Hov; Jochen Wedemeyer; Björn Lindkvist; Michael Wittig; Robert J Porte; Kristian Holm; Christian Gieger; H-Erich Wichmann; Pieter Stokkers; Cyriel Y Ponsioen; Heiko Runz; Adolf Stiehl; Cisca Wijmenga; Martina Sterneck; Severine Vermeire; Ulrich Beuers; Andreas Villunger; Erik Schrumpf; Konstantinos N Lazaridis; Michael P Manns; Stefan Schreiber; Tom H Karlsen
Journal:  Nat Genet       Date:  2010-12-12       Impact factor: 38.330

4.  Bone disease in patients with primary sclerosing cholangitis.

Authors:  Paul Angulo; Garfield A Grandison; Derek G Fong; Jill C Keach; Keith D Lindor; Einar Bjornsson; Alvaro Koch
Journal:  Gastroenterology       Date:  2010-10-16       Impact factor: 22.682

Review 5.  Classification, diagnosis, and management of cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-13       Impact factor: 11.382

Review 6.  Primary sclerosing cholangitis.

Authors:  Gideon M Hirschfield; Tom H Karlsen; Keith D Lindor; David H Adams
Journal:  Lancet       Date:  2013-06-28       Impact factor: 79.321

Review 7.  Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.

Authors:  Cyriel Y Ponsioen; Roger W Chapman; Olivier Chazouillères; Gideon M Hirschfield; Tom H Karlsen; Ansgar W Lohse; Massimo Pinzani; Erik Schrumpf; Michael Trauner; Gregory J Gores
Journal:  Hepatology       Date:  2015-12-23       Impact factor: 17.425

8.  Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.

Authors:  Jason T Lewis; Jayant A Talwalkar; Charles B Rosen; Thomas C Smyrk; Susan C Abraham
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

9.  A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts.

Authors:  Edward Alabraba; Peter Nightingale; Bridget Gunson; Stefan Hubscher; Simon Olliff; Darius Mirza; James Neuberger
Journal:  Liver Transpl       Date:  2009-03       Impact factor: 5.799

10.  Refinement of the MHC risk map in a scandinavian primary sclerosing cholangitis population.

Authors:  Sigrid Næss; Benedicte A Lie; Espen Melum; Marita Olsson; Johannes R Hov; Peter J P Croucher; Jochen Hampe; Erik Thorsby; Annika Bergquist; James A Traherne; Erik Schrumpf; Kirsten Muri Boberg; Stefan Schreiber; Andre Franke; Tom H Karlsen
Journal:  PLoS One       Date:  2014-12-18       Impact factor: 3.240
View more
  109 in total

1.  Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11.

Authors:  Tomohiro Katsumi; Maria Eugenia Guicciardi; Adiba Azad; Steven F Bronk; Anuradha Krishnan; Gregory J Gores
Journal:  Am J Physiol Cell Physiol       Date:  2019-07-31       Impact factor: 4.249

2.  The "gut microbiota" hypothesis in primary sclerosing cholangitis.

Authors:  Valerio Pontecorvi; Marco Carbone; Pietro Invernizzi
Journal:  Ann Transl Med       Date:  2016-12

3.  Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study.

Authors:  Yong Eun Park; Jae Hee Cheon; Jae Jun Park; Yoon Jae Kim; Chang Hwan Choi; Yehyun Park; Soo Jung Park; Tae Il Kim; Won Ho Kim
Journal:  Int J Colorectal Dis       Date:  2018-07-09       Impact factor: 2.571

4.  Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b.

Authors:  Konstantina Kyritsi; Fanyin Meng; Tianhao Zhou; Nan Wu; Julie Venter; Heather Francis; Lindsey Kennedy; Paolo Onori; Antonio Franchitto; Francesca Bernuzzi; Pietro Invernizzi; Kelly McDaniel; Romina Mancinelli; Domenico Alvaro; Eugenio Gaudio; Gianfranco Alpini; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-05-12       Impact factor: 4.307

5.  Effects of human amnion-derived mesenchymal stem cells and conditioned medium in rats with sclerosing cholangitis.

Authors:  Ryo Sugiura; Shunsuke Ohnishi; Masatsugu Ohara; Marin Ishikawa; Shuichi Miyamoto; Reizo Onishi; Koji Yamamoto; Kazumichi Kawakubo; Masaki Kuwatani; Naoya Sakamoto
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

Review 6.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 7.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

8.  Intestinal barrier regulates immune responses in the liver via IL-10-producing macrophages.

Authors:  Nobuhito Taniki; Nobuhiro Nakamoto; Po-Sung Chu; Yohei Mikami; Takeru Amiya; Toshiaki Teratani; Takahiro Suzuki; Tomoya Tsukimi; Shinji Fukuda; Akihiro Yamaguchi; Shunsuke Shiba; Rei Miyake; Tadashi Katayama; Hirotoshi Ebinuma; Takanori Kanai
Journal:  JCI Insight       Date:  2018-06-21

Review 9.  Early detection of intrahepatic cholangiocarcinoma.

Authors:  Mami Hamaoka; Kazuto Kozaka; Osamu Matsui; Takahiro Komori; Takashi Matsubara; Norihide Yoneda; Kotaro Yoshida; Dai Inoue; Azusa Kitao; Wataru Koda; Toshifumi Gabata; Satoshi Kobayashi
Journal:  Jpn J Radiol       Date:  2019-08-01       Impact factor: 2.374

Review 10.  An update on the management of cholestatic liver diseases.

Authors:  Gautham Appanna; Yiannis Kallis
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.